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Abstracts / Biol Blood Marrow Transplant 21 (2015) S266eS321S318(higher CT value), whereas the presence of an increased
number of symptoms (3) was associated with a higher
viral load. Lower viral load at initial surveillance testing
correlated with an increased likelihood of being asymp-
tomatic initially and remaining asymptomatic throughout
the viral shedding episode. These results provide initial
support for the use of viral load as a clinical endpoint in
interventional trials.460
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Background: Tacrolimus is extensively employed in allo-
geneic hematopoietic cell transplant (alloHCT) for the
prevention of graft-versus-host disease (GvHD). Renal and
hepatic toxicities have been associated with increased
blood concentrations post alloHCT. Due to the narrow
therapeutic index of tacrolimus and variability in blood
concentrations, drug monitoring is essential. Difﬁculties
of therapeutic monitoring include dosage forms limitedFigure A. Depletion of DNMT1 in HCT116-WT and DKO cells cultured with 0.5mM de
ﬂow cytometry in a patient with relapsed AML post-transplant who was treated with p
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after start of azacitidine. The DNMT1 level was determined in CD34+CD117+ and S-pto capsules, drug interactions, and changes in organ
function.
Methods: All patients were initiated on 0.005 mg/kg (ideal
body weight) intravenously every 12 hours on Day -1
through a central venous catheter. Tacrolimus trough levels
were drawn twice weekly by peripheral vein (Tuesday and
Fridays). Once levels were stable in the therapeutic range (5
to 15 ng/mlddesired target between 5 to 10 ng/ml), doses
were converted to the solution formulation of 1 mg/ml
(Elefante et al BBMT 2006). Datawere collected from January
2013 to March 2014.
Results: Eighty-seven patients were admitted for alloHCT
during this time period. Of these 87 patients, 527 tacrolimus
adjustments were performed. These adjustments resulted in
12 out of greater than 10,000 levels drawn to be outside the
upper recommended range of 15 ng/ml.
Conclusions: Tacrolimus adjustments utilizing the intrave-
nous and solution dosage forms allowed doses to be adjusted
in smaller increments minimizing the frequency of toxic
trough levels.461
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